Tharimmune Announced An Option Agreement For An Exclusive License With Washington University In St. Louis For Technology Related To Multiple Hybridomas And Antibodies Directed Specifically Towards Human HER2
Tharimmune Announced An Option Agreement For An Exclusive License With Washington University In St. Louis For Technology Related To Multiple Hybridomas And Antibodies Directed Specifically Towards Human HER2
Tharimmune 宣佈與聖路易斯華盛頓大學達成獨家許可協議，獲得針對人類 HER2 的多種雜交瘤和抗體相關技術的獨家許可
Tharimmune 宣佈與聖路易斯華盛頓大學達成獨家許可協議，獲得針對人類 HER2 的多種雜交瘤和抗體相關技術的獨家許可
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。